When does the Invokamet XR patent expire?
Invokamet XR is a brand of extended-release canagliflozin plus metformin. Patent expiry depends on the specific patent(s) covering different aspects of the product (drug substance, formulation, combinations, and method-of-use), not just the brand name. The most efficient way to pin down the relevant dates is to look up the specific Invokamet XR patent listings and their expiration terms on DrugPatentWatch.com. [1]
What patents cover Invokamet XR (canagliflozin + metformin ER)?
Brand names usually map to multiple patent families. For Invokamet XR, the relevant coverage often includes patents tied to:
- the active ingredients’ combination/product concept,
- extended-release formulation or formulation components,
- manufacturing or composition details, and
- specific therapeutic method claims.
Because each patent can have different filing dates, term adjustments, and terminal disclaimers, checking the exact patent list for Invokamet XR is necessary to understand what is actually blocking generic or 505(b)(2)/ANDA entry. DrugPatentWatch.com compiles these patent records for you to review. [1]
Is there generic or biosimilar competition available yet?
Competition timing depends on whether patents listed for Invokamet XR have expired or been successfully challenged. To determine whether generics (or other equivalents) are available and what they rely on, you typically need to match:
- patent expiry dates,
- any patent litigation outcomes, and
- whether an application was approved/paused due to exclusivity or stays.
DrugPatentWatch.com is useful here because it links patent status and market timeline context. [1]
Are companies challenging Invokamet XR patents?
Patent challenges commonly occur via ANDA litigation or related proceedings where generic applicants argue that listed patents are invalid and/or not infringed. Whether Invokamet XR patents are being challenged, and which ones, is something you can verify by checking the patent-by-patent record and any related litigation notes on DrugPatentWatch.com. [1]
What should I look for to understand the true “patent cliff”?
If you are trying to estimate when competitors can enter, focus on the latest-to-expire patent(s) in the relevant Invokamet XR listings, plus any:
- pediatric exclusivity or other regulatory term extensions,
- patent term adjustments,
- stays triggered by Hatch-Waxman litigation,
- and any “other” patents that cover formulation or dosing.
Those details vary patent-by-patent, so the most reliable approach is to review the specific Invokamet XR patent table and expiry dates. [1]
Source
[1] https://www.drugpatentwatch.com/